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Abstract
Background: Chemotheraputic drugs often target the microtubule cytoskeleton as a means to disrupt cancer cell mitosis
and proliferation. Anti-microtubule drugs inhibit microtubule dynamics, thereby triggering apoptosis when dividing cells
activate the mitotic checkpoint. Microtubule dynamics are regulated by microtubule-associated proteins (MAPs); however,
we lack a comprehensive understanding about how anti-microtubule agents functionally interact with MAPs. In this report,
we test the hypothesis that the cellular levels of microtubule depolymerases, in this case kinesin-13 s, modulate the
effectiveness of the microtubule disrupting drug colchicine.
Methodology/Principal Findings: We used a combination of RNA interference (RNAi), high-throughput microscopy, and
time-lapse video microscopy in Drosophila S2 cells to identify a specific MAP, kinesin-like protein 10A (KLP10A), that
contributes to the efficacy of the anti-microtubule drug colchicine. KLP10A is an essential microtubule depolymerase
throughout the cell cycle. We find that depletion of KLP10A in S2 cells confers resistance to colchicine-induced microtubule
depolymerization to a much greater extent than depletion of several other destabilizing MAPs. Using image-based assays,
we determined that control cells retained 58% (62%SEM) of microtubule polymer when after treatment with 2 mM
colchicine for 1 hour, while cells depleted of KLP10A by RNAi retained 74% (61%SEM). Likewise, overexpression of KLP10A-
GFP results in increased susceptibility to microtubule depolymerization by colchicine.
Conclusions/Significance: Our results demonstrate that the efficacy of microtubule destabilization by a pharmacological
agent is dependent upon the cellular expression of a microtubule depolymerase. These findings suggest that expression
levels of Kif2A, the human kinesin-13 family member, may be an attractive biomarker to assess the effectiveness of anti-
microtubule chemotherapies. Knowledge of how MAP expression levels affect the action of anti-microtubule drugs may
prove useful for evaluating possible modes of cancer treatment.
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Introduction
Microtubules (MTs) are cytoskeletal filaments composed of non-
covalent polymers of ab-tubulin heterodimers [1,2]. During
interphase, microtubules perform essential cellular processes
including organization of the cytoplasm, definition of cellular
shape and structure, positioning the nucleus and other cellular
organelles, and serving as structural components of cilia and
flagella [1]. MTs are 25 nm-wide hollow structures, composed of
thirteen polarized, linear protofilaments formed by the head-to-tail
association of ab-tubulin heterodimers. The structural polarity of
microtubules confers directionality to microtubule-associated
motors such as kinesin and dynein, as well as for the localization
of some microtubule-associated proteins (MAPs) [3].
While MT tracks form essential intracellular highways for the
transport of cellular material, they are not static structures. MTs
are highly dynamic and exhibit alternating phases of growth and
shrinkage, a behavior known as dynamic instability [1]. This
switching behavior between periods of growth and shrinkage is
influenced by the binding and hydrolysis of guanosine triphos-
phate (GTP) by the b-subunit of ab-tubulin heterodimers within
microtubules. GTP-bound tubulin exhibits a straight conformation
which favors incorporation into the growing plus end of the
microtubule by allowing lateral interaction between tubulins of
adjacent protofilaments. Once b-tubulin undergoes GTP hydro-
lysis shortly after incorporation into the microtubule lattice, the
heterodimer adopts a bent conformation which precludes these
lateral interactions and favors microtubule catastrophe [1]. The
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11381presence or absence of a stabilizing ‘‘cap’’ of GTP-tubulin at the
plus ends of microtubules influences the dynamicity of individual
polymers [4]. Dynamic instability is essential for a variety of
processes during interphase, including cell polarization and
subsequent movement, and the attachment of microtubules to
various cellular targets for intracellular trafficking. The dynamic
nature of the microtubule cytoskeleton is also of vital importance
during mitosis as it allows cells to assemble a mitotic spindle and to
find kinetochore attachment sites via a ‘‘search and capture’’
mechanism [1,5].
In addition to the normal fluctuations in microtubule dynamics
brought about by tubulin’s intrinsic GTPase activity, dynamic
instability can also be enhanced or suppressed by the actions of
MAPs. MAPs may be categorized into two types: conventional
stabilizing MAPs, which bind along the microtubule lattice and act to
bundle microtubules, and MT plus end-interacting proteins (+TIPs),
which preferentially associate with plus ends to regulate growth and
shrinkage. Someof these +TIPs, such as members of the XMAP215/
Dis1 family, act as MT polymerases that potently stimulate the
growth of MTs. Other +TIPs, such as the kinesin-13 sub-family, act
to triggerMTcatastrophe and act aspotent depolymerases. Thus,the
MT plus end is a key site for the regulation of MT behavior by MAPs
that exhibit antagonistic activities.
Drugs that actively disrupt MT dynamics prevent the proper
formation of the mitotic spindle and in doing so trigger apoptosis
in dividing cells. As transformed cells typically divide much more
quickly than non-transformed cells, anti-microtubule agents are
often useful as chemotherapeutic cancer treatments [4,6]. Thus,
small molecules that disrupt the mitotic spindle have been
attractive targets to specifically kill cancer cells [7–9]. Many
anti-MT agents, such as colchicine, nocadazole, and vinblastine,
function by binding to ab-tubulin heterodimers to interfere with
MT polymerization and have proven to be highly effective at
preventing cancer cell proliferation [10–12]. Despite the impor-
tance of MT-disrupting small molecules as chemotherapeutics, we
know very little about whether these drugs act in concert with
MAPs or how MAP expression levels might affect the efficacy of
drug treatment.
Previous research suggested that variable expression levels of the
mammalian kinesin-13, MCAK, altered the effectiveness of anti-
MT drugs on human cancer cells [9]. In this study, we present the
effects of depletion and of kinesin-13 family members and other
MAPs in Drosophila S2 cells treated with anti-microtubule drugs.
Knowledge of how MAPs such as these modulate anti-microtubule
drug effectiveness could be used to assess possible modes of
chemotherapy treatment for cancer patients. These experiments
suggest that the kinesin-13, KLP10A, is of particular importance for
the activity of the anti-MT drug colchicine. Drosophila S2 cells
exhibit increased resistance to colchicine-induced MT depolymer-
ization when depleted of this protein and increased susceptibility to
drug treatment upon over-expression of KLP10A-GFP. Our results
suggest that expression levels of Kif2A,the human kinesin-13 family
member, may be a useful biomarker to predict the effectiveness of
anti-microtubule agents in various cancers. Moreover, they predict
that allosteric small molecule activators of kinesin-13 family
members could act to potentiate the effectiveness of anti-
microtubule drugs in chemotherapeutic strategies.
Results
RNAi-mediated depletion of KLP10A confers resistance to
colchicine treatment
In order to determine if the expression level of MAPs affected
the sensitivity of S2 cells to anti-MT treatment, we began our
study by performing a targeted RNAi screen to deplete cells of
known MT-destabilizing proteins. The proteins examined were
the three Drosophila kinesin-13s (KLP10A, KLP59C, and KLP9D).
This group was chosen due to the fact that they exhibit
microtubule destabilizing functions in a variety of contexts and
they were therefore considered as potential candidates to alter
anti-microtubule drug action. Furthermore, previous work sug-
gested that kinesin-13s may antagonize anti-microtubule drug
action during mitosis, thus the Drosophila kinesin-13 family
members were of particular interest [9]. Initial analysis of the
affects of protein knockdowns on anti-microtubule drug action
were conducted by visual examination of the morphology of the
microtubule cytoskeleton in colchicine treated vs. DMSO treated
cells of each RNAi condition. Control RNAi-treated (SK) cells
exhibited fairly extensive microtubule loss upon 1 mM colchicine
treatment for 1 hour (Fig. 1 A,B). KLP10A RNAi knockdowns, on
the other hand, were relatively resistant to drug treatment, with
microtubules that closely resembled DMSO control-treated
KLP10A knockdowns (Fig. 1 C,D). S2 cells depleted of KLP10A
appeared remarkably resistant to colchicine in this initial
observation. For the other RNAi knockdowns, no dramatic
changes in sensitivity to colchicine treatment were observed by
eye. While this experiment provided convincing images suggesting
the involvement of KLP10A in colchicine-induced microtubule
depolymerization, we developed additional assays for more
quantitative analyses of MT polymer levels.
Quantitative analysis of colchicine resistance using high-
throughput microscopy
After the initial qualitative observation of the resistance to
colchicine in cells lacking KLP10A, we used high-throughput
image cytometry to measure this effect quantitatively. Our strategy
was to use RNAi to deplete kinesin-13 protein levels and prepare
samples for immunofluorescence using fixation protocols that
simultaneously extracted soluble tubulin so that only microtubule
polymer contributed to the fluorescence signal from the samples.
To measure the effect of KLP10A depletion on the efficacy of
colchicine-induced microtubule depolymerization, cells were
plated in 96-well format, treated with 2 mM colchicine, and
stained for DNA and microtubules. We then used a high-
throughput imaging system that autofocused on and identified cells
by fluorescence in the DNA channel and then dilated an image
mask of the nucleus in the MT channel to acquire a measurement
of the average microtubule immunofluorescence pixel intensity
across 1,700–2,000 cells in each well. Measurement of average
microtubule immunofluorescence provided a quantitative measure
of the relative sensitivity to colchicine treatment in cells depleted of
the collection of MT destabilizing factors. S2 cells treated with
negative control SK dsRNA retained 58% (62%SEM) of total
microtubule polymer after colchicine treatment as compared to
control DMSO-treated cells. KLP10A RNAi knockdowns retained
a much larger portion of total microtubule polymer after drug
treatment: 73% (61%SEM) (Fig. 2A). Depletion of the other
kinesin-13s, KLP59C and KLP59D, did not result in statistically
significant differences from controls with respect to cellular
susceptibility to drug treatment (Fig. 2A,). The effectiveness of
these RNAi knockdowns was evaluated by western blot analysis of
cell lysates from each RNAi condition (Fig. 2B, 2C). KLP10A
RNAi resulted in a 99% decrease in protein levels and KLP59C
RNAi resulted in a 76% reduction in protein levels. We were
unable to validate KLP59D knockdown by western blot analysis as
we lacked specific antibodies to the protein and have not yet
generated KLP59D-GFP constructs which could be used for
western blotting. However, previous research suggests that
KLP10A Potentiates Colchicine
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[13], supporting the idea that KLP59D would have no effect on
colchine-induced MT depolymerization during interphase. From
these data, we conclude that depletion of KLP10A protects cells
from MT destabilization by colchicine.
Over-expression of KLP10A in S2 cells results in greater
sensitivity to colchicine treatment
As the depletion of KLP10A conferred increased resistance to
colchicine treatment in S2 cells, we next examined the
susceptibility of MTs to colchicine in S2 cells over-expressing
KLP10A. We co-transfected S2 cells with expression vectors for
KLP10A-EGFP and mCherry-tubulin driven by the metallothio-
nine promoter and induced expression overnight with 100 mM
copper sulfate. Transient transfection typically produces a
population of cells with a range of expression levels of the
constructs due to variation in the number of copies of the plasmid
delivered. We then performed time-lapse imaging on a spinning
disk confocal microscope and observed MT depolymerization
during perfusion with colchicine. S2 cells expressing high levels of
KLP10A-GFP, as determined by relative GFP fluorescence
intensities, exhibited a much greater sensitivity to colchicine
treatment, as their MT polymer levels decreased at a faster rate
than MTs in cells not expressing the KLP10A transgene (Fig. 3,
Movie S1). These time-lapse movies suggest that over-expression
of KLP10A-GFP causes an increase in the kinetics and extent of
microtubule depolymerization by colchicine.
Time-lapse imaging provided compelling support for the
involvement of KLP10A in colchicine-induced microtubule
depolymerization. In order to correlate the relationship between
KLP10A expression levels and susceptibility to drug treatment, S2
cells were transfected with only KLP10A-GFP and induced to
express high levels of the construct. We then treated the cells with
colchicine, fixed them, and stained for microtubules. We acquired
images of cells expressing a range of KLP10A-GFP and measured
the average pixel intensities for microtubule immunofluorescence
and KLP10A-GFP fluorescence (Fig. 4 A,B). We found a very
clear correlation between the level of expression of KLP10A-GFP
and increased sensitivity to colchicine in S2 cells (m=22.932,
p,0.0001, Fig. 4D). We treated parallel samples with DMSO as a
negative control for colchicine treatment and found only a slight
negative correlation between the amount of KLP10A-GFP and the
amount of microtubule polymer in each cell (m=20.5801,
p=.291, Fig. 4C), however, this was to be expected as KLP10A
is known to function as a microtubule de-stabilizer [14]. We
also controlled for the possibility that expression of GFP itself
rendered cells more susceptible to colchicine by transfecting S2
cells with a GFP-peroxisome marker and subjected to the same
procedure (Fig. 5). As shown in Figure 5, the presence of GFP in
cells had no correlative effect on colchicine-induced microtubule
depolymerization. This also demonstrates the amount of colchi-
cine-induced MT depolymerization in cells without the presence
of exogenous KLP10A. Colchicine-induced MT depolymerization
appears less extensive in cells expressing only endogenous levels of
KLP10A.
Figure 1. RNAi-mediated depletion of KLP10A protects microtubules from depolymerization by colchicine. (A,B) Drosophila S2 cells
were cultured with negative control dsRNA for seven days, then either treated with DMSO (A) or 1 mM colchicine (B) for 1 hr and processed for
immunofluorescence to visualize the microtubule cytoskeleton. Note the short microtubule fragments remaining after colchicine treatment in (B).
(C,D) S2 cells were cultured with dsRNAs to deplete KLP10A for seven days, then treated with either DMSO (C) or colchicine (D) as described. Note
that microtubules in (D) closely resemble those in control cells (C). Bar=5 mm.
doi:10.1371/journal.pone.0011381.g001
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The data presented here demonstrate that the expression level
of a particular MT depolymerase alters the effectiveness of the
anti-MT drug colchicine. RNAi depletion of KLP10A in S2 cells
confers greater resistance to colchicine-induced MT depolymer-
ization, and likewise, over-expression of a KLP10A construct
causes increased cellular susceptibility to colchicine treatment.
While some resistance to drug-induced microtubule depolymer-
ization might be expected when cells are depleted of a protein that
promotes microtubule depolymerization, neither of the other
kinesin-13 family members tested caused such a drastic alteration
of cellular susceptibility to drug treatment. This suggests that
KLP10A may have a unique role in this process. This supports the
idea that Kif2A, the human homologue of KLP10A, may be an
attractive biomarker for assessing the effectiveness of potential
anti-MT chemotherapy treatments. In addition, the development
of drugs or small molecules that alter kinesin-13 activity could
prove therapeutically useful in combination with anti-MT drugs.
However, further investigation into this matter is still needed to
determine the effects of altered expression of other kinesin-13s on
colchicine action, and how depletion and over-expression of these
proteins affects the action of other anti-MT drugs.
A potential mechanism that would explain the results presented
in this paper has become apparent. Previous research has shown
that kinesin-13s bind preferentially to GDP-tubulin in curved
protofilaments at the plus ends of MTs [15,16]. Colchicine is
known to bind at the intra-dimer cleft in between the a- and b-
subunits of tubulin heterodimers and induce a conformational
change in tubulin from the straight GTP-bound conformation to
one that mimics the bent GDP-bound conformation. These
soluble tubulin-colchicine complexes are then incorporated into
microtubule polymers and promote microtubule catastrophe [10].
An increased presence of tubulin-colchicine complexes in
Figure 2. Total microtubule polymer levels are protected from colchicine upon depletion of KLP10A in cell populations as
determined using high-throughput microscopy. (A) Populations of cells were either treated with SK dsRNA as a negative control, KLP10A
dsRNA, KLP59C dsRNA, or KLP59D dsRNA for 7 days and processed for immunofluorescence to visualize microtubules and DNA in 96-well plates.
Individual wells were scanned using a high-throughput microscope to acquire images of 1700-2000 cells per well. The imaging system software was
programmed to identify individual nuclei in the DNA channel and to dilate nuclear objects to generate masks of individual cell outlines. These cellular
masks were then used to measure the average fluorescence pixel intensity per cell in the microtubule channel for each treatment. The graph is a
representative replicate of the results obtained for 3 independent duplicate experiments. When comparing %MT polymer remaining after drug
treatment, only KLP10A knockdowns showed statistically significant differences from controls (p,0.0001). KLP59C and KLP59D knockdowns were not
statistically significant from controls with respect to the amount of MT polymer remaining after colchicine treatment (p=0.1942 and p=0.3651,
respectively). Western Blots of cell lysates are shown demonstrating KLP10A knockdown (B) and KLP59C knockdown (C) by RNAi. Using densitometry
we calculated RNAi knockdown efficiencies to be 99% reduction of KLP10A and 76% reduction of KLP59C protein levels. A parallel tubulin blot is
shown as a loading control.
doi:10.1371/journal.pone.0011381.g002
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may provide KLP10A with a higher cellular concentration of
potential substrate on which to act. KLP10A may then be able to
localize more efficiently to these microtubules with large amounts
of tubulin-colchicine complexes and cause rapid microtubule
depolymerization. When KLP10A is not present, however, the
cellular machinery appears to be less capable of depolymerizing
microtubules. This suggests that KLP10A is either recruited more
extensively to these positions, or is more active during colchicine-
induced MT depolymerization, than other kinesin-13s. These
details remain to be determined.
In the future, we will continue to investigate the effects of altered
expression levels of MAPs on the susceptibility of S2 cells to other
anti-MT drugs. Specific drugs of interest include the vinca-
alkaloid, vinblastine, and taxol. Furthermore, the effect of
overexpression of KLP59C and KLP59D on the susceptibility
of S2 cells to colchicine remains to be tested. As cellular depletion
of these proteins did not cause a drastic change in susceptibility to
colchicine treatment, we predict that overexpression will similarly
have little effect on the action of colchicine. It will also be
interesting to determine if the presence of stabilizing MAPs
required for MT growth also confer resistance to anti-MT drugs.
Experiments testing these ideas are currently underway in the
laboratory.
Colchicine is not currently used to treat cancer, but its potential
for use as a chemotherapy drug has received significant
investigation. However, many of the anti-microtubule drugs that
are used as chemotherapy treatments cause nearly identical
cellular phenotypes at similar concentrations and have been shown
to bind both tubulin heterodimers and the microtubule lattice in a
similar manner to colchicine [10]. This suggests that other anti-
microtubule drugs, such as the vinca alkaloids, may also exhibit
variation in effectiveness when expression levels of specific MAPs
are altered.
Many anti-microtubule drugs are currently used as chemother-
apy treatments and broader knowledge as to how the expression
levels of MAPs affect the activity of these drugs would be especially
valuable. If the gene expression profiles of proteins that effect anti-
microtubule drug action can be obtained for different cancer sub-
types, more appropriate and effective modes of chemotherapy
treatment could be selected for cancer patients. Drugs could
potentially be prescribed that would optimize treatment outcomes
and minimize side-effects.
Materials and Methods
S2 Cell Culture and Double Stranded RNAi
Drosophila S2 cells were obtained from the Drosophila Genome
Resource Center (Bloomington, IN). S2 culture and RNAi were
performed as previously described [17].
We used the following primer sets to perform RNAi. A DNA
sequence from the pBluescript SK plasmid (SK) that has no
homology in the Drosophila genome was used as a negative control
for RNAi. RNAi against the mitotic kinesin, Pavarotti, was
performed in parallel as a positive control as they fail to undergo
cytokinesis and become multinucleated, providing a visual assay of
knockdown effectiveness. For RNAi, 7 mg of dsRNA/mL media
was added to cultured S2 cells once/day for 7–9 days. Templates
Figure 3. Increased KLP10A expression levels confers sensitivity to colchicine as determined using live-cell microscopy. S2 cells were
cotransfected with plasmids encoding KLP10A-EGFP and mCherry-tubulin and image using time-lapse spinning disk confocal microscopy. Images
were acquired at 10 second intervals and cells were perfused with 4 mM colchicine approximately 170s in to the sequence. Note that the rate of
microtubule depolymerization is greater in cells with the highest levels of expression of KLP10A-EGFP. By approx. t=500 s the cell expressing high
levels of KLP10A-EGFP has nearly no MT polymer while the MT cytoskeleton in the neighboring cell remains relatively unaffected.
doi:10.1371/journal.pone.0011381.g003
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by using primers that began with the T7 promoter on the 59
primer 59-TAATACGACTCACTATAGGG-39 and continue
with gene specific sequences listed here. The primers were
(forward and reverse): Pavarotti (59 – AATGTGTTCTGTC-
GAGTGCG – 39 and 59 – AGCAAAACGCTGGTTCATCT –
39), SK (59-TAAATTGTAAGCGTTAATATTTTG-39 and 59-
AATTCGATATCAAGCTTATCGAT-39), KLP10A: (59-AT-
GATTACGGTGGGGCA-39 and 59-GACATCGATCT CCTT-
GCG-39), KLP59C: (59-ATGGATAAGTTGTCGATCG-39 and
59-ACCAGGTTCACATGCTTGCG-39), KLP59D: (59-GGA-
TCGCATCAAAATTGG-39 and 59-CGTAGACCAGCGCA-
TTG-39).
Immunofluorescence Microscopy
RNAi-treated S2 cells were plated on Concanavalin A (ConA)
coated coverslips and fixed in 10% formaldehyde in BRB80 buffer
(80 mM PIPES, 1 mM magnesium chloride, 1 mM EDTA,
pH 6.9) at room temperature for 10 min. For high throughput
analysis, cells were fixed in 10% formaldehyde, 0.1% Saponin in
BRB80 buffer for 3 min, and then in 10% formaldehyde in
BRB80 (without Saponin) for 7 min. The presence of this
additional step with detergent for the first three minutes (0.1%
Saponin) further removed the cytosolic pool of unpolymerized
tubulin that would otherwise contribute to background fluores-
cence when imaging and quantifying MT pixel intensities. The
cells were then washed in phosphate buffered saline (PBS) plus
0.1% Triton X100 (PBST), followed by blocking with 5% normal
goat serum (NGS) in PBST. The primary antibody used was an
anti-a-tubulin antibody (DM1a, Sigma-Aldrich, St. Louis, MO).
After treatment with fluorescently labeled secondary antibodies
(Cy3 – Jackson ImmunoResearch Laboratories) and AlexFluor488
Phalloidin (Invitrogen) for 1 hr, cells were stained for DNA with
Hoechst (Invitrogen) at a final concentration of 10 mg/mL.
Samples were mounted in Dako Fluorescent Mounting Medium
and imaged using a Nikon Eclipse Ti-E microscope equipped with
a 10061.45NA Nikon objective and CoolSnap HQ cooled CCD
camera.
High-Throughput Microscopy for Quantification of
Microtubule Polymer Levels in RNAi Knockdown Cells
RNAi knockdown S2 cells were seeded on ConA coated 96-well
dishes (Nunc-Clear-96 plates) at a density of 30,000 cells per well
for ,1.5 hr, treated with 2 uM colchicine in Schneider’s Medium
Figure 4. Overexpression of KLP10A-GFP in Drosophila S2 cells confers increased susceptibility to colchicine treatment. S2 cells were
transfected, induced to express KLP10A-GFP, treated with 1 mM colchicine for 1 hour, then processed for immunofluorescence to visualize
microtubules. A representative transfected cell is shown in the tubulin channel (A) and GFP channel (B). Note extensive loss of microtubules in (A). In
order to test for a correlation between expression levels of KLP10A-GFP and the extent of microtubule depolymerization, individual transfected cells
were imaged in both channels and microtubule polymer levels and KLP10A-GFP expression levels were determined by measuring average
fluorescent pixel intensities per cell. Bar =5 mm. The results are plotted for control DMSO-treated cells (C) and colchicine-treated cells (D). The
amount of KLP10A-GFP in DMSO treated cells (C) did not show a statistically significant effect on the amount of MT polymer present (p=0.291).
However, when transfected cells were treated with colchicine (D) a strong negative correlation is observed between the amount of KLP10A-GFP
present and the amount of MT polymer present (p,0.0001).
doi:10.1371/journal.pone.0011381.g004
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py), and scanned with an Array Scan V (Cellomics) equipped with
a4 0 6 NA 0.95 objective and a cooled charge-coupled device
camera (ORCA-ER; Hamamatsu Photonics). Images of 1,700–
2,000 cells per well were acquired and analyzed using vHCS View
(Cellomics). Objects in each well were identified by DNA staining
and average object microtubule fluorescence pixel intensity
measurements for each well were determined from these images.
S2 Cell Transfections and Live Imaging
Fluorescent constructs of mCherry-Tubulin, KLP10A-GFP,
and a GFP Peroxisome marker in Invitrogen pMT vectors were
transfected into Drosophila S2 cells via electroporation using the
Nucleofector II (Amaxa) apparatus. Cells were allowed ,24 hrs in
Schneider’s medium to recover after transfection. Expression of
the constructs was then induced for ,18 hrs by addition of
100 mM CuSO4.
Induced cells were plated on ConA coated MatTek glass-
bottom dishes for at least 1 hr. before observation. Samples were
imaged using a 100X NA 1.45 PlanApochromat objective (Nikon)
using a spinning disc confocal (Yokogawa: Perkins-Elmer)
mounted on a microscope (Eclipse TE300: Nikon) with a z-focus
motor (Prior Scientific), and excitation and emission wheel
controlled by a Lambda 10-2 controller (Sutter Instrument Co.),
an interline transfer-cooled charge-coupled device camera (OR-
CA-ER, Hamamatsu Photonics), and emission filters (Semrock).
Images were acquired for time-lapse movies once every 10 s for
approx. 15 min time spans using MetaMorph software (MDS
Analytical Technologies). Colchicine was added to the medium to
a final concentration of 4 mM at about frame 17 (approx. 170 s)
and microtubule depolymerization was recorded in time-lapse
videos.
Supporting Information
Movie S1 S2 cells were cotransfected with plasmids encoding
KLP10A-EGFP and mCherry-tubulin and image using time-lapse
spinning disk confocal microscopy. Images were acquired at 10
second intervals and cells were perfused with 4 mM colchicine
approximately 170s in to the sequence. Note that the rate of
microtubule depolymerization is greater and more extensive in the
cell expressing high levels of KLP10A-EGFP.
Found at: doi:10.1371/journal.pone.0011381.s001 (5.66 MB
MOV)
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Figure 5. GFP expression alone does not protect microtubules from colchicine. As a negative control, S2 cells were transfected with a
plasmid expressing GFP targeted to peroxisomes, either treated with DMSO or colchicine, and processed as described in Figure 3 to visualize
microtubules (A) and peroxisomes (B). Bar =5 mm. The plots show average microtubule pixel intensity per cell plotted against GFP peroxisome
average pixel intensity per cell. The amount of Peroxisome-GFP did not show a statistically significant effect on the amount of MT polymer present in
DMSO-treated cells (p=0.7966, C) or colchicine-treated cells (p=0.9046, D).
doi:10.1371/journal.pone.0011381.g005
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